Industry-Sponsored Research Week
University-Industry Engagement Advisor

U Chicago and AbbVie sign five-year extension of oncology research collaboration

By David Schwartz
Published: November 16th, 2021

The University of Chicago has extended a preclinical oncology research collaboration with AbbVie through 2025, hoping to build on an already successful partnership.

Thus far, the collaboration has led to novel insights related to biomarkers and therapeutic applications for existing AbbVie programs, including novel drug delivery approaches to enhance anti-tumor immune response and unique 3D screening methodologies for selecting novel therapeutic molecules.

“Our oncology collaboration with the University of Chicago enables us to combine our expertise in understanding the underlying biology in key areas of interest, such as immuno-oncology, oncogenic pathways, and biomarkers of drug sensitivity or disease,” said Steve Davidsen, vice president of oncology discovery research at AbbVie. “This effort drives towards a common goal of accelerating discovery efforts and delivering novel therapies to people living with cancer.” 

Like the initial deal, the extension is designed to accelerate and advance medical research in oncology at both organizations.

“Our ambition is that the clinical and translational collaboration between AbbVie and the University of Chicago continues to impact public health positively,” said Kunle Odunsi, MD, PhD, AbbVie Foundation Director with the University of Chicago Medicine Comprehensive Cancer Center. “The collaboration has created valuable opportunities for scientific exchange and the development of clinical trials for cancer research.”

Under the agreement, AbbVie get an option for an exclusive license to certain U Chicago discoveries made as part of the collaboration.

“We look forward to more discoveries together in the years to come,” said Juan de Pablo, University of Chicago vice president for national laboratories, science strategy, innovation, and global initiatives. “The extension of our agreement will continue to provide faculty and students with opportunities to work with colleagues at a global biopharmaceutical leader and translate their findings from the lab into the real world. It will enable the kind of preclinical research that is needed to help lay the foundations for better approaches and treatments with the goal to ultimately improve quality of life for patients.”

Source: Cision

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment